{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:25:13Z","timestamp":1789503913750,"version":"build-2803163510"},"reference-count":41,"publisher":"Impact Journals, LLC","issue":"51","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,10,24]]},"DOI":"10.18632\/oncotarget.19153","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T15:05:55Z","timestamp":1499785555000},"page":"89307-89314","source":"Crossref","is-referenced-by-count":23,"title":["Silibinin: an old drug for hematological disorders"],"prefix":"10.18632","volume":"8","author":[{"given":"Hai","family":"Zou","sequence":"first","affiliation":[{"name":"Department of Cardiology, Zhejiang Provincial People's Hospital, Hangzhou 310000, China"},{"name":"People\u2019s Hospital of Hangzhou Medical College, Hangzhou 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Xing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Zhejiang Provincial People's Hospital, Hangzhou 310000, China"},{"name":"People\u2019s Hospital of Hangzhou Medical College, Hangzhou 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Bing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou 310000, China"},{"name":"People\u2019s Hospital of Hangzhou Medical College, Hangzhou 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhejiang Provincial People's Hospital, Hangzhou 310000, China"},{"name":"People\u2019s Hospital of Hangzhou Medical College, Hangzhou 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zhejiang Provincial People's Hospital, Hangzhou 310000, China"},{"name":"People\u2019s Hospital of Hangzhou Medical College, Hangzhou 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Sheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Zhejiang Provincial People's Hospital, Hangzhou 310000, China"},{"name":"People\u2019s Hospital of Hangzhou Medical College, Hangzhou 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,7,11]]},"reference":[{"key":"1","unstructured":"Zhu, Ding, Wu, Qian, Zou, He. Silibinin: a potential old drug for cancer therapy. Expert Rev Clin Pharmacol. 2016; pp. 1\u20138."},{"key":"2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/cam4.186","article-title":"Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer","volume":"3","author":"Waller","year":"2014","journal-title":"Cancer Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.intimp.2013.04.016","article-title":"Immunomodulatory effects of silymarin in patients with beta-thalassemia major","volume":"16","author":"Amirghofran","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"4","first-page":"47","article-title":"Secondary iron overload","author":"Olivieri","year":"2001","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"5","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1086\/315919","article-title":"Effect of transfusional iron overload on immune response","volume":"182","author":"De Sousa","year":"2000","journal-title":"J Infect Dis"},{"key":"6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/03630269.2010.544624","article-title":"Increased oxidative stress and iron overload in Jordanian beta-thalassemic children","volume":"35","author":"Ahmad","year":"2011","journal-title":"Hemoglobin"},{"key":"7","first-page":"8","article-title":"Effects of Vitamin E and Zinc Supplementation on Antioxidants in Beta thalassemia major Patients","volume":"21","author":"Joshaghani","year":"2011","journal-title":"Iran J Pediatr"},{"key":"8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12291-008-0074-7","article-title":"Oxidative stress and disturbance in antioxidant balance in beta thalassemia major","volume":"23","author":"Joshi","year":"2008","journal-title":"Indian J Clin Biochem"},{"key":"9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1472-8206.2009.00681.x","article-title":"Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial","volume":"23","author":"Amirghofran","year":"2009","journal-title":"Fundam Clin Pharmacol"},{"key":"10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/ejh.12061","article-title":"A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in beta-thalassemia major patients receiving desferrioxamine","volume":"90","author":"Jalaeikar","year":"2013","journal-title":"Eur J Haematol"},{"key":"11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/08923973.2014.926916","article-title":"Serum levels of TGFbeta, IL-10, IL-17, and IL-23 cytokines in beta-thalassemia major patients: the impact of silymarin therapy","volume":"36","author":"Moayedi","year":"2014","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"12","doi-asserted-by":"crossref","first-page":"e2013065","DOI":"10.4084\/mjhid.2013.065","article-title":"Therapeutic value of combined therapy with deferasirox and silymarin on iron overload in children with Beta thalassemia","volume":"5","author":"El-Lateef","year":"2013","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","article-title":"Acute myeloid leukemia","volume":"341","author":"Burnett","year":"1999","journal-title":"N Engl J Med"},{"key":"14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3322\/caac.21314","article-title":"Cancer statistics for Hispanics\/Latinos, 2015","volume":"65","author":"Jemal","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"15","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"\u2018Acute myeloid leukemia: a comprehensive review and 2016 update\u2019","volume":"6","author":"Abdul-Hay","year":"2016","journal-title":"Blood Cancer J"},{"key":"16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/01635581003693082","article-title":"Distinct combinatorial effects of the plant polyphenols curcumin, carnosic acid, and silibinin on proliferation and apoptosis in acute myeloid leukemia cells","volume":"62","author":"Danilenko","year":"2010","journal-title":"Nutr Cancer"},{"key":"17","first-page":"401784","article-title":"Cell-Type-Specific Effects of Silibinin on Vitamin D-Induced Differentiation of Acute Myeloid Leukemia Cells Are Associated with Differential Modulation of RXRalpha Levels","volume":"2012","author":"Danilenko","year":"2012","journal-title":"Leuk Res Treatment"},{"key":"18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.leukres.2009.09.010","article-title":"Vitamin D3-driven signals for myeloid cell differentiation\u2014implications for differentiation therapy","volume":"34","author":"Brown","year":"2010","journal-title":"Leuk Res"},{"key":"19","first-page":"1487","article-title":"Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C","volume":"61","author":"Kim","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"20","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/jcp.20355","article-title":"Cooperation between antioxidants and 1,25-dihydroxyvitamin D3 in induction of leukemia HL60 cell differentiation through the JNK\/AP-1\/Egr-1 pathway","volume":"204","author":"Studzinski","year":"2005","journal-title":"J Cell Physiol"},{"key":"21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/hon.929","article-title":"Silibinin can induce differentiation as well as enhance vitamin D3-induced differentiation of human AML cellsand regulates the levels of differentiation-related transcription factors","volume":"28","author":"Studzinski","year":"2010","journal-title":"Hematol Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.4161\/cc.9.22.13790","article-title":"Inhibition of Cot1\/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3)","volume":"9","author":"Studzinski","year":"2010","journal-title":"Cell Cycle"},{"key":"23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4103\/0973-1482.157330","article-title":"Enhancement of the cytotoxic effects of Cytarabine in synergism with Hesperidine and Silibinin in Acute Myeloid Leukemia: Anapproach","volume":"11","author":"Rawal","year":"2015","journal-title":"J Cancer Res Ther"},{"key":"24","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1200\/JCO.1994.12.5.895","article-title":"Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin\u2019s lymphoma","volume":"12","author":"Lin","year":"1994","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/10428199809068562","article-title":"The t(2;5) in human lymphomas","volume":"29","author":"Morris","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"26","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1182\/blood-2007-04-060715","article-title":"Pathobiology of ALK+ anaplastic large-cell lymphoma","volume":"110","author":"Lai","year":"2007","journal-title":"Blood"},{"key":"27","doi-asserted-by":"crossref","first-page":"550","DOI":"10.2174\/187152009788451851","article-title":"The PI3K\/Akt pathway as a target in the treatment of hematologic malignancies","volume":"9","author":"Yamada","year":"2009","journal-title":"Anticancer Agents Med Chem"},{"key":"28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/cr.2008.18","article-title":"STAT3 as a target for inducing apoptosis in solid and hematological tumors","volume":"18","author":"Turkson","year":"2008","journal-title":"Cell Res"},{"key":"29","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2002-12-3647","article-title":"Map kinase signaling pathways and hematologic malignancies","volume":"101","author":"Platanias","year":"2003","journal-title":"Blood"},{"key":"30","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood-2007-02-071258","article-title":"The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1\/2 and JunB translation via mTOR signaling","volume":"110","author":"Bergler","year":"2007","journal-title":"Blood"},{"key":"31","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1038\/bcj.2012.27","article-title":"Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma","volume":"2","author":"Lai","year":"2012","journal-title":"Blood Cancer J"},{"key":"32","first-page":"1154","article-title":"Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma","volume":"57","author":"Lai","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"33","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","article-title":"Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma","volume":"6","author":"Los","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"34","first-page":"6266","article-title":"Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib","volume":"8","author":"Garate","year":"2016","journal-title":"Rare Tumors"},{"key":"35","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1080\/15384101.2016.1245249","article-title":"STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer","volume":"15","author":"Bosch-Barrera","year":"2016","journal-title":"Cell Cycle"},{"key":"36","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"Bornhauser","year":"2015","journal-title":"Lancet"},{"key":"37","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.3892\/mmr.2016.4887","article-title":"Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K\/Akt\/mTOR signaling pathway","volume":"13","author":"Guo","year":"2016","journal-title":"Mol Med Rep"},{"key":"38","doi-asserted-by":"publisher","first-page":"7625","DOI":"10.18632\/oncotarget.13825","article-title":"Discovery of a novel Nrf2 inhibitor that induces apoptosis of human acute myeloid leukemia cells","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"39","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.24723","article-title":"A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL)","volume":"116","author":"Kelly","year":"2010","journal-title":"Cancer"},{"key":"40","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ctrv.2015.04.008","article-title":"Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy","volume":"41","author":"Menendez","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"41","doi-asserted-by":"publisher","first-page":"32006","DOI":"10.18632\/oncotarget.7900","article-title":"Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin","volume":"7","author":"Menendez","year":"2016","journal-title":"Oncotarget"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T11:02:53Z","timestamp":1719313373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,11]]},"references-count":41,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2017,10,24]]}},"alternative-id":["19153","29179521"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.19153","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,11]]}}}